The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
BUSINESS
Santen Gets Asian Rights to Aerie’s Glaucoma Meds
Santen Pharmaceutical said on October 28 that it has obtained exclusive rights to develop and commercialize two glaucoma medicines of US drug maker Aerie Pharmaceuticals in Japan and several other Asian countries. Aerie is an ophthalmic specialty firm focused on…
To read the full story
Related Article
- Glaucoma Eye Drop Rocklatan Now Available in Singapore: Santen
March 14, 2025
- Santen’s Glaucoma Med Rhopressa Hits Shelves in South Korea
November 5, 2024
- Santen Bags Global Rights to Aerie’s Glaucoma Meds, Except US, in Expanded Pact
December 8, 2021
BUSINESS
- Novartis CEO Touts Plan to Amp Up Japan Investment, Add 50 Jobs for Early Trials
March 18, 2025
- Kissei to Run Additional PIII for Spinocerebellar Degeneration Drug
March 17, 2025
- Novel β-Lactamase Inhibitor Nacubactam Safe and Effective: Meiji
March 17, 2025
- AbbVie Files Migraine Med Atogepant in Japan
March 17, 2025
- Zeria’s Hyperkalemia Drug Veltassa Now Available in Japan
March 17, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…